Biotech stocks have taken investors on an unpredictable ride so far in 2023. One of the most popular biotech exchange-traded funds (ETFs), the iShares Biotechnology ETF, which focuses mostly on large-cap stocks, is down by about 1% year to date. However, the SPDR S Biotech ETF, which holds more small or mid-cap stocks, is up more than 8% to start the year.

Two of the better biotech stocks I see this month are Gilead Sciences (NASDAQ: GILD) and Vertex Pharmaceuticals (NASDAQ: VRTX). While Gilead's shares are down more than 11% so far this year, Vertex's shares are up more than 14%. Yet, each has strong financials. Plus, each company has a particular specialty that has served it well, and both are aiming to branch out into other therapy areas.

Let's see why each would make a good buy now.

Continue reading

Source Fool.com